Service
Standard antidepressants couldn’t crack your depression. Spravato was engineered for that exact failure point. Our Spravato treatment clinic in Karns TN provides the only FDA-approved esketamine nasal spray for adults whose depression has resisted conventional medication — and most insurance covers it.
REMS-Certified Esketamine Therapy — The First New Class of Antidepressant in Over Three Decades
Karns has changed a lot over the past decade. What was once a rural pocket northwest of Knoxville has grown into one of Knox County’s most sought-after communities — young families filling new subdivisions along Byington-Solway Road, local businesses expanding along Oak Ridge Highway, and a school system that draws people from across the region. But growth doesn’t insulate a community from treatment-resistant depression. If anything, the pressures of work, family, and daily life in a fast-moving area can make untreated mental health conditions harder to manage.
If you’ve taken two or more antidepressants and your depression hasn’t meaningfully improved, there’s a clinical term for that: treatment-resistant depression. There’s also, finally, an FDA-approved solution. Spravato (esketamine nasal spray) represents the first genuinely new class of antidepressant medication approved in more than thirty years — and Revitalist is a fully REMS-certified provider just minutes from Karns via Pellissippi Parkway.
What Spravato treatment in Karns TN through Revitalist means for you:
The first new mechanism of action for depression treatment since the introduction of SSRIs
FDA approval backed by a clinical trial program involving more than 1,700 patients
Insurance coverage through most commercial and government plans for qualifying patients
Symptom improvement documented within 24 hours of the initial dose
Supervised nasal spray — no IVs, no injections, no hospital stays
83% of our patients report significant improvement after completing their initial treatment series.
“Breakthrough” gets thrown around loosely in medicine. In Spravato’s case, the FDA agreed. They literally granted it Breakthrough Therapy designation — a status reserved for drugs that demonstrate substantial improvement over existing treatments for serious conditions. Here’s why that matters.
Why Spravato Stands Apart:
First New Mechanism in 30+ Years: Every prior antidepressant adjusted monoamines. Spravato targets glutamate through NMDA receptor modulation — a fundamentally different approach
Breakthrough Therapy Designation: The FDA reserved this status for drugs showing substantial improvement over available therapies
Speed That Changes the Equation: Phase 3 data showed measurable improvement within 24 hours — compared to the four-to-eight-week wait standard antidepressants require
Insurance Access: FDA approval unlocked coverage through most major plans, putting advanced treatment within financial reach
Proven Staying Power: The SUSTAIN trials confirmed that continuing Spravato treatment maintained remission and significantly reduced relapse risk
A pivotal study published in JAMA Psychiatry confirmed that patients who continued Spravato treatment after achieving remission experienced significantly lower relapse rates than those switched to placebo. Among patients in stable remission, those who stayed on esketamine maintained their gains at rates that far outperformed the control group — critical evidence that Spravato doesn’t just produce temporary relief but sustains it over time.
Speed of Relief
Spravato® Therapy
Hours to days
Traditional Antidepressants
Success Rate
Spravato® Therapy
Traditional Antidepressants
10-30% for treatment-resistant cases
Spravato® Therapy
Often covered for approved indications
Traditional Antidepressants
Generally covered but limited effectiveness
Mechanism of Action
Spravato® Therapy
Glutamate/NMDA system
Traditional Antidepressants
Serotonin/dopamine systems
Spravato® Therapy
Traditional Antidepressants
Daily self-administered pills
Spravato® Therapy
Traditional Antidepressants
Often persistent and ongoing
“I coach youth baseball in Karns and run a small landscaping crew during the week. From the outside, everything looked normal. On the inside, I’d been going through the motions for three years. My doctor tried Lexapro, then Effexor, then Wellbutrin. Nothing landed. When he mentioned Spravato treatment in Karns TN through Revitalist, I figured I was running out of options anyway. After my fourth session, I caught myself planning a weekend trip to Norris Dam with my kids — not because I felt obligated, but because I actually wanted to go. I can’t remember the last time I’d felt that way.”
— Chris A., Karns, TN Patient
“Menopause triggered a depression that completely blindsided me. I’d never dealt with mental health issues before, and suddenly I couldn’t function. Two years, three antidepressants, and one therapist later, I was barely holding it together. My gynecologist referred me to the best Spravato treatment clinic in Karns area at Revitalist. The first session felt strange — the nasal spray was easy, but the dreamlike sensation caught me off guard. By my third visit, I woke up feeling something I can only describe as lightness. My husband said my eyes looked different. Less flat. That was week two, and the improvement has held.”
— Denise F., Karns, TN Patient
“I work in IT at a company off Pellissippi, and remote work during the pandemic pushed a manageable depression into something unbearable. Isolation, no boundaries between work and home, drinking more than I should have. My psychiatrist worked through two SSRIs and an SNRI before we both agreed the standard playbook wasn’t cutting it. She sent me to the Spravato treatment clinic in Karns TN area, and honestly, the insurance coverage was what got me in the door — I couldn’t have afforded IV ketamine out of pocket. Five sessions in, the fog cleared enough for me to start exercising again, reconnect with friends, and actually log off at the end of the day.”
— Ryan M., Karns, TN Patient
That’s not a subtle distinction — it’s the whole point. Spravato reaches the glutamate system your previous medications never touched, using the first new antidepressant mechanism the FDA has approved in over thirty years.
Spravato carries specific FDA indications, and our broader clinical menu addresses the full range of treatment-resistant conditions Karns residents face:
When two or more antidepressants haven’t provided adequate relief
Rapid intervention for patients with active suicidal thoughts
If you’ve already tried multiple antidepressants without success, understanding why they failed helps explain why Spravato works. It’s not a mystery — it’s pharmacology.
Glutamate is the brain’s primary excitatory neurotransmitter — responsible for roughly 90% of excitatory signaling. It governs synaptic transmission, neural plasticity, memory consolidation, and the brain’s capacity to adapt and restructure. When glutamate signaling deteriorates, the consequences look clinically identical to serotonin-based depression: flattened mood, cognitive impairment, anhedonia, fatigue. But the underlying biology is distinct, which is why serotonin-targeted medications don’t address it.
The S-enantiomer formulation in Spravato binds NMDA receptors with approximately four times the affinity of the R-enantiomer, concentrating the therapeutic effect while producing fewer dissociative side effects than racemic ketamine at equivalent antidepressant potency.
From 1987 until 2019, every FDA-approved antidepressant manipulated monoamine neurotransmitters. SSRIs blocked serotonin reuptake. SNRIs added norepinephrine. Bupropion targeted dopamine. Tricyclics and MAOIs worked through less selective monoamine interactions. Each drug came with different dosing and side effect profiles, but underneath, they were all pulling the same levers.
For about two-thirds of patients, those levers move something useful. For the remaining third — the treatment-resistant population — monoamines aren’t the core problem. Adjusting serotonin in someone whose depression stems from glutamate dysregulation is like tuning the radio when the antenna is broken. The signal was never the issue.
Spravato’s approval rested on a Phase 3 program spanning more than 1,700 patients across multiple international trial sites. The TRANSFORM studies established short-term efficacy. The SUSTAIN studies proved long-term maintenance. And the 2025 monotherapy trial confirmed that Spravato works as a standalone treatment, with remission rates nearly three times higher than placebo at four weeks.
Dr. Thase, one of the principal investigators, noted that each time a standard treatment fails, the consequences compound — marriages fracture, careers collapse, children lose a present parent. Spravato addresses that urgency by compressing the treatment timeline from months to hours, giving patients a functional window they can use to rebuild.
Your first visit is a detailed consultation. Our physicians review your psychiatric history, examine which medications you’ve tried and at what doses, and determine whether your depression meets the clinical threshold for treatment resistance. We also screen for conditions that might make Spravato inappropriate — certain cardiovascular issues, pregnancy, or a history of psychotic disorders.
Insurance verification starts during this visit. Our team manages the entire prior authorization process, documents your treatment history for your carrier, and provides a transparent cost estimate before anything begins. Karns residents leave their consultation knowing exactly where things stand.
Our Knoxville clinic at 10608 Flickenger Lane is easily reached from Karns — south on Pellissippi Parkway, then west. The drive takes roughly fifteen minutes. When you arrive, we measure your blood pressure and do a quick clinical check-in.
You self-administer the Spravato nasal spray under our team’s direct supervision. It takes about fifteen minutes. The spray device is simple — two sprays per device, with your prescribed dose determining whether you use two or three devices per session. There are no needles and no IV setup.
After dosing, you spend two hours in a private treatment room while our staff monitors your vitals and checks on you periodically. Patients use this time in different ways. Some bring noise-canceling headphones. Some close their eyes and rest. A few keep a journal. Whatever helps you relax — we accommodate it.
Spravato follows an FDA-defined dosing structure:
We work hand-in-hand with your Karns-area psychiatrist, therapist, or primary care physician. Spravato produces its best results as part of a coordinated treatment strategy, and we keep every provider in the loop through direct communication, shared progress documentation, and collaborative decision-making.
Every Spravato provider must hold REMS certification. That's the minimum. At Revitalist, we've integrated REMS protocols into the DNA of our clinical operation — from staff training and patient monitoring to documentation and emergency preparedness. When you walk into the best Spravato treatment clinic in Karns, the safety infrastructure is invisible precisely because it's everywhere.
Prior authorization for Spravato involves clinical documentation, treatment history verification, and carrier-specific protocols. Our team handles it all. We know the requirements for every major insurer, and we've streamlined the process so Karns patients get approved quickly and start treatment without unnecessary delays.
Our physicians aren't experimenting with Spravato. They've administered thousands of ketamine and esketamine treatments across years of focused clinical practice. That depth of experience translates directly into better dosing decisions, more effective management of side effects, and stronger outcomes for every patient.
Most Spravato sessions involve two hours of monitored observation. In a cold clinical space, that's a long wait. In our purpose-built treatment rooms — warm lighting, comfortable seating, privacy, and a genuinely welcoming atmosphere — it becomes time patients value. Several have told us it's the only two hours in their week where they genuinely relax.
Knox County Community Development works to strengthen services and quality of life across the county, and expanding mental health access has become an increasing priority for communities like Karns. Revitalist contributes by making FDA-approved, insurance-covered treatment available locally — so residents don't have to leave the region for care that changes lives.
Not everyone is best served by Spravato. Not everyone is best served by IV ketamine. We offer both — plus complementary services — and let your clinical picture determine the recommendation: Spravato (Esketamine) — FDA-approved, insurance-covered nasal spray for treatment-resistant depression IV Ketamine Therapy — Intravenous delivery for treatment-resistant depression, PTSD, anxiety, chronic pain, and additional conditions Vitamin Infusion Therapy — Brain health and recovery support alongside primary treatment
Spravato® safety profile has been studied extensively through Phase 3 clinical trials involving thousands of patients, plus years of real-world use since its 2019 approval. The REMS program exists to ensure that every administration occurs under conditions designed to minimize risk.
These effects typically resolve within 1-2 hours after treatment ends. Our medical team provides continuous monitoring throughout your session and observation period to ensure your comfort and safety.
Spravato® therapy may not be appropriate for individuals with:
During your consultation, our medical team will thoroughly review your health history and current medications to determine if Spravato® therapy is safe and appropriate for you.
Many patients report noticeable improvements within hours or days of their first treatment. Unlike traditional antidepressants that can take 4-8 weeks to show effects, Spravato’s rapid action through the glutamate system often provides relief during the first treatment session.
The FDA-approved protocol includes twice-weekly treatments for the first month (induction phase), weekly treatments for the second month (maintenance phase), and then weekly or bi-weekly treatments based on your response (continuation phase). Your specific protocol will be customized based on your individual needs and response to treatment.
Yes, many major insurance plans cover Spravato for FDA-approved indications like treatment-resistant depression. Coverage typically requires prior authorization and documentation of previous treatment failures. Our team will verify your specific benefits and guide you through the approval process.
No, you cannot drive or operate machinery until the next day after receiving Spravato. You must arrange transportation home after each session. This is a mandatory safety requirement due to the medication’s effects on cognition and coordination.
Your first session will begin with final preparations and a review of the self-administration process. You’ll use the simple nasal spray device under our medical team’s supervision, then relax in our comfortable treatment room during the required 2-hour monitoring period. Our staff will ensure your comfort and safety throughout the entire process.
Spravato is FDA-approved specifically for treatment-resistant depression and is often covered by insurance, while ketamine infusions are used off-label for various conditions and typically aren’t covered. Spravato is self-administered as a convenient nasal spray, while ketamine requires IV infusion. Both contain the same active compound but in different formulations.
Yes, Spravato was specifically developed and FDA-approved for treatment-resistant depression. Clinical trials demonstrated significant effectiveness in patients who had failed to respond to multiple previous antidepressants. The unique glutamate mechanism offers hope when serotonin-based treatments haven’t provided relief.
No, Spravato is designed to be used alongside an oral antidepressant as combination therapy. You should continue your current medications unless specifically directed otherwise by your healthcare provider. Our medical team will review your medications and coordinate with your psychiatrist as needed.
Long-term studies show that continued Spravato treatment can provide sustained improvement in depression symptoms with manageable side effects. The SUSTAIN studies demonstrated that patients who responded to initial treatment could maintain their improvement with ongoing therapy. Regular monitoring ensures safe, effective long-term use.
Take the first step toward healing:
Free Assessment
Personalized treatment plan designed for your specific condition
Rapid relief often within hours of your first treatment
Insurance coverage verification and prior authorization support
Compassionate care from experienced mental health professionals
